Moreover, while the activation of Wnt/β-catenin and SDF-1/CXCR4 signaling was supported by molecular evidence, the precise functional consequences of pharmacological inhibition of these pathways in different prostate cancer subtypes and stromal contexts warrant further investigation. The gene discussed is CXCR4; the disease is Familial prostate cancer.